Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Daiichi Sankyo and the University of California, San Francisco, have formed a drug discovery collaboration focused on neurodegenerative diseases. Daiichi Sankyo will provide its compound library to the UC San Francisco Institute for Neurodegenerative Diseases, and the partners will jointly perform high-throughput compound screening. Meanwhile, the Belgian drug company UCB has formed a research partnership with Weill Cornell Medical College. UCB will fund research programs in bone disorders, metabolic disease, and rare-genetic-variant analysis.
This article has been sent to the following recipient: